Comparative assessment of short-termadverse events in acute heart failure withcystatin C and other estimates of renal function: Results from the ASCEND-HF trial

JACC: Heart Failure

Volumn 3, Issue 1, 2015, Pages 40-49

  Tang, W H Wilson ^a   Dupont, Matthias ^b   Hernandez, Adrian F ^c   Voors, Adriaan A ^d   Hsu, Amy P ^a   elker, G Michael ^c   Butler, Javed ^e   Metra, Marco ^f   Anker, Stefan D ^g   Troughton, Richard W ^h   Gottlieb, Stephen S ⁱ   McMurray, John J ^j   Armstrong, Paul W ^k   Massie, Barry M ^l   Califf, Robert M ^c   O'Connor, Christopher M ^c   Starling, Randall C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DEPARTMENT OF CARDIOLOGY   (Belgium)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e STONY BROOK UNIVERSITY   (United States)

^f UNIVERSITY OF BRESCIA   (Italy)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^h UNIVERSITY OF OTAGO   (New Zealand)

ⁱ UNIVERSITY OF MARYLAND   (United States)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k UNIVERSITY OF ALBERTA   (Canada)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Acute heart failure; Cystatin C; Nesiritide; Renal insufficiency

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; NESIRITIDE; NITROGEN; PLACEBO; SODIUM; UREA; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

ACUTE HEART FAILURE; AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; ACUTE DISEASE; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; FOLLOW UP; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; AGED; CYSTATIN C; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84920287346     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.06.014     Document Type: Article

References (28)

1. Tang W.H., Mullens W. Cardiorenal syndrome in decompensated heart failure. Heart 2010, 96:255-260.
2. Metra M., Cotter G., Gheorghiade M., Dei Cas L., Voors A.A. The role of the kidney in heart failure. Eur Heart J 2012, 33:2135-2142.
3. Lassus J., Harjola V.P. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev 2012, 17:251-261.
4. Shlipak M.G., Mattes M.D., Peralta C.A. Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis 2013, 62:595-603.
5. Lassus J., Harjola V.P., Sund R., et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007, 28:1841-1847.
6. Lassus J.P., Harjola V.P., Peuhkurinen K., et al. Cystatin C, NT-proBNP, and inflammatory markers in acute heart failure: insights into the cardiorenal syndrome. Biomarkers 2011, 16:302-310.
7. Damman K., van der Harst P., Smilde T.D., et al. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart 2012, 98:319-324.
8. Dupont M., Wu Y., Hazen S.L., Tang W.H. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail 2012, 5:602-609.
9. Shlipak M.G., Katz R., Fried L.F., et al. Cystatin-C and mortality in elderly persons with heart failure. JAm Coll Cardiol 2005, 45:268-271.
10. Tang W.H., Van Lente F., Shrestha K., et al. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. JCard Fail 2008, 14:394-399.
11. Shlipak M.G., Matsushita K., Arnlov J., et al. Cystatin C versus creatinine in determining risk based on kidney function. NEngl J Med 2013, 369:932-943.
12. Inker L.A., Levey A.S. Pro: estimating GFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 creatinine equation: the time for change is now. Nephrol Dial Transplant 2013, 28:1390-1396.
13. McAlister F.A., Ezekowitz J., Tarantini L., et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-EpidemiologyCollaboration group formula. Circ Heart Fail 2012, 5:309-314.
14. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. NEngl J Med 2011, 365:32-43.
15. Hernandez A.F., O'Connor C.M., Starling R.C., et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 2009, 157:271-277.
16. Felker G.M., Hasselblad V., Tang W.H., et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. Eur J Heart Fail 2012, 14:1257-1264.
17. Inker L.A., Schmid C.H., Tighiouart H., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. NEngl J Med 2012, 367:20-29.
18. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
19. Inker L.A., Shaffi K., Levey A.S. Estimating glomerular filtration rate using the chronic kidneydisease-epidemiology collaboration creatinine equation: better risk predictions. Circ Heart Fail 2012, 5:303-306.
20. Bragadottir G., Redfors B., Ricksten S.E. Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury: true GFR versus urinary creatinine clearance and estimating equations. Crit Care 2013, 17:R108.
21. Colombo P.C., Onat D., Harxhi A., et al. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J 2014, 35:448-454.
22. Ganda A., Onat D., Demmer R.T., et al. Venous congestion and endothelial cell activation in acute decompensated heart failure. Curr Heart Fail Rep 2010, 7:66-74.
23. Lassus J.P., Nieminen M.S., Peuhkurinen K., et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 2010, 31:2791-2798.
24. Dupont M., Mullens W., Finucan M., Taylor D.O., Starling R.C., Tang W.H. Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. Eur J Heart Fail 2013, 15:433-440.
25. Testani J.M., McCauley B.D., Kimmel S.E., Shannon R.P. Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure. Am J Cardiol 2010, 106:1763-1769.
26. Gottlieb S.S., Stebbins A., Voors A.A., et al. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure). JAm Coll Cardiol 2013, 62:1177-1183.
27. Metra M., Cotter G., Davison B.A., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. JAm Coll Cardiol 2013, 61:196-206.
28. Chen H.H., Anstrom K.J., Givertz M.M., et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013, 310:2533-2543.